EV
EVAX.US Evaxion Biotech AS
- Market cap
- USD 25.3M
- P/E
- -
- P/B
- 2.66x
- ROE
- -154.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is EVAX.US undervalued?
Graham numberThe Graham number of Evaxion Biotech AS cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Evaxion Biotech AS fundamental analysis
No fundamental analysis for Evaxion Biotech AS yet.
Evaxion Biotech AS stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Evaxion Biotech AS
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which…
Full company profileEvaxion Biotech AS financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Evaxion Biotech AS annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 73.0K | 3.34M | 7.53M | 0.00 |
| Gross Profit | -73.9K | -81.0K | -106K | -343K | -571K | 73.0K | 3.34M | 7.53M | - |
| Operating Income | -5.63M | -11.4M | -16.6M | -25.8M | -25.3M | -22.2M | -14.7M | -9.23M | -15.3M |
| EBITDA | -6.18M | -11.9M | -16.5M | -24.2M | -22.6M | -21.4M | -9.79M | -7.12M | -14.7M |
| Net Income | -5.54M | -11.2M | -15.0M | -24.5M | -23.2M | -22.1M | -10.6M | -7.71M | -14.7M |
| EPS | -12 | -28 | -37 | -50 | -39 | -32 | -9.85 | -1.20 | -35 |
| Balance Sheet | |||||||||
| Total Assets | 8.51M | 11.1M | 12.0M | 40.2M | 22.0M | 12.9M | 12.5M | 28.4M | 19.4M |
| Total Liabilities | 9.44M | 1.72M | 4.93M | 7.73M | 13.7M | 17.6M | 14.1M | 11.4M | 9.85M |
| Shareholders' Equity | -931K | 9.36M | 7.04M | 32.4M | 8.30M | -4.73M | -1.65M | 17.0M | 9.53M |
| Cash & Short-term Investments | 7.43M | 9.56M | 5.83M | 32.2M | 13.2M | 5.58M | 5.05M | 23.2M | 14.0M |
| Total Debt | 8.67M | 36.0K | 20.0K | 3.69M | 10.3M | 10.9M | 10.1M | 7.50M | 7.10M |
| Cash Flow | |||||||||
| Operating Cash Flow | -1.99M | -7.03M | -12.4M | -21.9M | -25.8M | -17.7M | -12.9M | -6.65M | - |
| Capital Expenditure | 7.00K | 61.0K | 393K | 1.36M | 292K | 87.0K | 4.69 | 11.0K | 0.00 |
| Free Cash Flow | -2.00M | -7.09M | -12.8M | -23.3M | -26.1M | -17.8M | -12.9M | -6.66M | - |
| Ratios | |||||||||
| ROE | - | -119.6% | -213.4% | -75.6% | -279.0% | - | - | -45.2% | -154.3% |
| ROA | -65.0% | -101.0% | -125.5% | -61.1% | -105.2% | -171.7% | -84.6% | -27.1% | -75.9% |
| Net Profit Margin | - | - | - | - | - | -30,308.2% | -316.0% | -102.4% | - |
| Debt to Equity | - | 0.00x | 0.00x | 0.11x | 1.24x | - | - | 0.44x | 0.75x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Evaxion Biotech AS dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | USD 165K | 0.41 | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:5 on Jan 14, 2025.
Who owns Evaxion Biotech AS
- Insiders 15.81%
- Institutions 9.48%
- Public & others 74.71%
- Shares outstanding 9.22M
- Free float 5.68M
Top funds holding EVAX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| PSM Value Strategy UI | 109K | 1.20% | +35.96% | Aug 2026 |
| PSM Macro Strategy | 83.3K | 0.92% | 0.00% | Sep 2026 |
| PSM Growth UI | 7.50K | 0.08% | +50.99% | Aug 2026 |
Top institutions holding EVAX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Merck & Co Inc | 1.21M | 13.46% | 0.00% | Jun 2026 |
| Ikarian Capital, LLC | 74.7K | 0.83% | 0.00% | Jun 2026 |
| Rathbone Brothers PLC | 45.7K | 0.51% | -50.00% | Jun 2026 |
| Citadel Advisors Llc | 36.6K | 0.41% | +105.84% | Jun 2026 |
| Renaissance Technologies Corp | 33.8K | 0.37% | -13.83% | Jun 2026 |
| Annis Gardner Whiting Capital Advisors LLC | 30.0K | 0.33% | 0.00% | Jun 2026 |
| J. Safra Sarasin Holding AG | 22.9K | 0.25% | 0.00% | Jun 2026 |
| Rhumbline Advisers | 21.8K | 0.24% | +0.88% | Jun 2026 |
| Jane Street Group LLC | 20.6K | 0.23% | 0.00% | Jun 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 18.4K | 0.20% | 0.00% | Jun 2026 |
| Stonepine Capital Management Llc | 17.6K | 0.19% | -10.91% | Jun 2026 |
| SmartHarvest Portfolios, LLC | 13.5K | 0.15% | -2.52% | Jun 2026 |
| XTX Topco Ltd | 12.9K | 0.14% | -41.51% | Jun 2026 |
| WesBanco Bank Inc | 10.0K | 0.11% | 0.00% | Jun 2026 |
| Northwestern Mutual Wealth Management Co | 8.00K | 0.09% | 0.00% | Jun 2026 |
| UBS Group AG | 6.28K | 0.07% | 0.00% | Jun 2026 |
| GAMMA Investing LLC | 4.61K | 0.05% | -11.27% | Jun 2026 |
| Integrated Wealth Concepts LLC | 642.00 | 0.01% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 62.00 | 0.00% | 0.00% | Jun 2026 |
| Bessemer Group Inc | 18.00 | 0.00% | 0.00% | Jun 2026 |
Evaxion Biotech AS company profile
- Company name
- Evaxion Biotech AS
- Ticker
- EVAX.US
- Exchange
- USA Stocks
- Listed since
- Feb 5, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 46
- Fiscal year end
- December
- Address
- Dr. Neergaards Vej, Horsholm, Denmark, 2970
- Phone
- 45 53 53 18 50
- Website
- evaxion.ai
About Evaxion Biotech AS
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Evaxion Biotech AS management
5- Dr. Helen Katrina Tayton-Martin MBA, Ph.D.Chief Executive Officer · born 1967
- Mr. Andreas Holm Mattsson M.Sc.Founder & Chief AI Officer · born 1971
- Mr. Thomas Frederik Schmidt M.Sc.Chief Financial Officer · born 1971
- Dr. Birgitte Rono Ph.D.Chief Scientific Officer & COO · born 1977
- Mr. Benjamin Ole WolthersVice President of Clinical Development